Drug Search Results
More Filters [+]

Telbermin

Alternative Names: telbermin
Latest Update: 2017-05-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: VEGF Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Telbermin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Diabetic Foot

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

VGF3554g

P2

Completed

Diabetic Foot

2008-01-01

VGF2763g

P1

Completed

Diabetic Foot

2004-10-01

Recent News Events

Date

Type

Title